EP3524230 - PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.06.2022 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 09.07.2021 | ||
Former | Grant of patent is intended Status updated on 10.03.2021 | ||
Former | Request for examination was made Status updated on 21.02.2020 | ||
Former | The application has been published Status updated on 12.07.2019 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Alkahest, Inc. 125 Shoreway Road, Suite D San Carlos, CA 94070 / US | [2019/33] | Inventor(s) | 01 /
FETSCHER, Alfred Boehringer Ingelheim GmbH, Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE | 02 /
SCHER, Jochen Matthias Boehringer Ingelheim GmbH, Corporate Patents Binger Strasse 173 55216 Ingelheim Am Rhein / DE | [2019/33] | Representative(s) | Grund, Martin Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2 80538 München / DE | [N/P] |
Former [2019/33] | Grund, Martin Grund Intellectual Property Group Patentanwalt und Solicitor PartG mbB Postfach 44 05 16 80754 München / DE | Application number, filing date | 18213458.5 | 02.04.2013 | [2019/33] | Priority number, date | EP20120163078 | 04.04.2012 Original published format: EP 12163078 | [2019/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3524230 | Date: | 14.08.2019 | Language: | EN | [2019/33] | Type: | B1 Patent specification | No.: | EP3524230 | Date: | 11.08.2021 | Language: | EN | [2021/32] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 10.07.2019 | Classification | IPC: | A61K9/00, A61K9/20, A61K9/28, A61K9/48, A61K31/4545, A61K9/16, A61P1/04, A61P17/00 | [2021/07] | CPC: |
A61K31/4545 (EP,KR,US);
A61K9/2054 (EP,KR,US);
A61K9/0053 (EP,US);
A61K9/1617 (EP,US);
A61K9/2009 (KR);
A61K9/2013 (EP,KR,US);
A61K9/2018 (EP,KR,US);
A61K9/2027 (EP,KR,US);
A61K9/2031 (EP,KR,US);
A61K9/2059 (KR);
A61K9/2077 (EP,US);
A61K9/2813 (KR,US);
A61K9/284 (EP,KR,US);
A61K9/2853 (US);
A61K9/2866 (EP,KR,US);
A61K9/4858 (KR,US);
A61K9/4866 (KR,US);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (KR);
A61P13/12 (EP);
A61P17/00 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P21/04 (EP);
A61P27/02 (EP);
A61P29/00 (EP,KR);
A61P31/00 (EP,KR);
A61P35/00 (EP);
A61P37/00 (EP,KR);
A61P37/02 (EP);
A61P37/06 (EP);
A61P37/08 (EP,KR);
A61P43/00 (EP);
|
Former IPC [2019/33] | A61K9/00, A61K9/20, A61K9/28, A61K9/48, A61K31/4545, A61P29/00, A61K9/16 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/13] |
Former [2019/33] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | PHARMAZEUTISCHE FORMULIERUNGEN MIT CCR3-ANTAGONISTEN | [2019/33] | English: | PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS | [2019/33] | French: | FORMULATIONS PHARMACEUTIQUES COMPRENANT DES ANTAGONISTES DE CCR3 | [2019/33] | Examination procedure | 13.02.2020 | Amendment by applicant (claims and/or description) | 13.02.2020 | Examination requested [2020/13] | 13.02.2020 | Date on which the examining division has become responsible | 11.03.2021 | Communication of intention to grant the patent | 01.07.2021 | Fee for grant paid | 01.07.2021 | Fee for publishing/printing paid | 01.07.2021 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP13714618.9 / EP2833864 | Divisional application(s) | EP21190323.2 / EP3970693 | Opposition(s) | 12.05.2022 | No opposition filed within time limit [2022/29] | Fees paid | Renewal fee | 25.03.2019 | Renewal fee patent year 03 | 25.03.2019 | Renewal fee patent year 04 | 25.03.2019 | Renewal fee patent year 05 | 25.03.2019 | Renewal fee patent year 06 | 25.03.2019 | Renewal fee patent year 07 | 16.03.2020 | Renewal fee patent year 08 | 26.04.2021 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 11.08.2021 | CY | 11.08.2021 | CZ | 11.08.2021 | EE | 11.08.2021 | HR | 11.08.2021 | LT | 11.08.2021 | LV | 11.08.2021 | MC | 11.08.2021 | MK | 11.08.2021 | RO | 11.08.2021 | RS | 11.08.2021 | SI | 11.08.2021 | SK | 11.08.2021 | SM | 11.08.2021 | TR | 11.08.2021 | BG | 11.11.2021 | GR | 12.11.2021 | LU | 02.04.2022 | [2024/29] |
Former [2024/23] | AL | 11.08.2021 | |
CY | 11.08.2021 | ||
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
MK | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
LU | 02.04.2022 | ||
Former [2024/20] | AL | 11.08.2021 | |
CY | 11.08.2021 | ||
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
LU | 02.04.2022 | ||
Former [2023/08] | AL | 11.08.2021 | |
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
LU | 02.04.2022 | ||
Former [2023/06] | AL | 11.08.2021 | |
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
MC | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/36] | AL | 11.08.2021 | |
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SI | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/29] | AL | 11.08.2021 | |
CZ | 11.08.2021 | ||
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/25] | CZ | 11.08.2021 | |
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SK | 11.08.2021 | ||
SM | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/24] | CZ | 11.08.2021 | |
EE | 11.08.2021 | ||
HR | 11.08.2021 | ||
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
RO | 11.08.2021 | ||
RS | 11.08.2021 | ||
SK | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/10] | HR | 11.08.2021 | |
LT | 11.08.2021 | ||
LV | 11.08.2021 | ||
RS | 11.08.2021 | ||
BG | 11.11.2021 | ||
GR | 12.11.2021 | ||
Former [2022/09] | LT | 11.08.2021 | |
RS | 11.08.2021 | ||
BG | 11.11.2021 | ||
Former [2022/08] | LT | 11.08.2021 | |
BG | 11.11.2021 | Documents cited: | Search | [XDI]WO2010115836 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-7,11,14 * examples 135, 142, 150 * * page 127, line 38 - page 128, line 41 * * page 46, line 13 - line 45 * * page 132; example B * * page 125 - lines 2, 4-5 * * page 126, lines 6, 8 * [I] 1-15; | [XPI]WO2012045803 (BOEHRINGER INGELHEIM INT [DE], et al) [XP] 1-7,11,14 * page 11, lines 6-21 * * page 50, lines 1-4 * * page 53, line 31 * * page 54, lines 1-2 * * pages 61-62; example B) * * claim - *[I] 1-15; | [Y] - GERBER B O ET AL, "Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils", CURRENT BIO, CURRENT SCIENCE, GB, (19971101), vol. 7, no. 11, doi:10.1016/S0960-9822(06)00371-X, ISSN 0960-9822, pages 836 - 843, XP004671726 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/S0960-9822(06)00371-X | [Y] - AMERIO PAOLO ET AL, "Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications", CURRENT DRUG TARGETS. INFLAMMATION AND ALL, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (20030301), vol. 2, no. 1, ISSN 1568-010X, pages 81 - 94, XP009139038 [Y] 1-15 * abstract * * page 7/17, paragraph "Atopic dermatitis" - page 8/17 * | [Y] - LIANNE I. WILLEMS ET AL, "Small molecule antagonists for chemokine CCR3 receptors", MEDICINAL RESEARCH REVIEWS, US, (20090101), doi:10.1002/med.20181, ISSN 0198-6325, pages n/a - n/a, XP055598161 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1002/med.20181 | by applicant | WO2010115836 | - LUSTER, New Eng. J Med., (19980000), vol. 338, pages 436 - 445 | - ROLLINS, Blood, (19970000), vol. 90, pages 909 - 928 | - LLOYD, Curr. Opin. Pharmacol., (20030000), vol. 3, pages 443 - 448 | - MURRAY, Current Drug Targets, (20060000), vol. 7, pages 579 - 588 | - SMIT, Eur J Pharmacol, (20060000), vol. 533, pages 277 - 88 | - HORUK, Trends Pharm. Sci., (19940000), vol. 15, pages 159 - 165 | - MURPHY, Pharmacol Rev., (20020000), vol. 54, no. 2, pages 227 - 229 | - ALLEN, Annu. Rev. Immunol., (20070000), vol. 25, pages 787 - 820 | - BEN-BARRUCH et al., Cell, (19930000), vol. 72, pages 415 - 425 | - LUSTER, New Eng. J. Med., (19980000), vol. 338, pages 436 - 445 | - CHARO et al., Proc. Natl. Acad. Sci. USA, (19940000), vol. 91, pages 2752 - 2756 | - COMBADIERE et al., J. Biol. Chem., (19950000), vol. 270, pages 16491 - 16494 | - POWER et al., J. Biol. Chem., (19950000), vol. 270, pages 19495 - 19500 | - SANSON et al., Biochemistry, (19960000), vol. 35, pages 3362 - 3367 | - BABA et al., J. Biol. Chem., (19970000), vol. 272, pages 14893 - 14898 | - YOSHIE et al., J. Leukoc. Biol., (19970000), vol. 62, pages 634 - 644 | - NAPOLITANO et al., J. Immunol., (19960000), vol. 157, pages 2759 - 2763 | - BERNARDINI et al., Eur. J. Immunol., (19980000), vol. 28, pages 582 - 588 | - BONINI et al., DNA and Cell Biol., (19970000), vol. 16, pages 1249 - 1256 | - SCHWEICKART et al., J Biol Chem, (20000000), vol. 275, pages 9550 - 9556 | - WELLS; SCHWARTZ, Curr. Opin. Biotech., (19970000), vol. 8, pages 741 - 748 | - COMERFORD, Bioessays., (20070000), vol. 29, no. 3, pages 237 - 47 | - WEGMANN, Am J Respir Cell Mol Biol., (20070000), vol. 36, no. l, pages 61 - 67 | - FRYER, J Clin Invest., (20060000), vol. 116, no. 1, pages 228 - 236 | - DE LUCCA, Curr Opin Drug Discov Devel., (20060000), vol. 9, no. 4, pages 516 - 524 | - WATSON PS, Bioorg Med Chem Lett., (20060000), vol. 16, no. 21, pages 5695 - 5699 | - DE LUCCA, J Med Chem., (20050000), vol. 48, no. 6, pages 2194 - 2211 | - LIST et al., Arzneiformen-lehre, Wissenschaftliche Verlagsgesellschaft mbH, page 70ff | - VOIGT R., Lehrbuch der pharmazeutischen Technologie [Textbook of Pharmaceutical Technology, Verlag Chemie, page 148 | - TAKEDA et al., Nature, (20090000), vol. 460, no. 7252, pages 225 - 30 |